Aesthetic medicine of the new generation

M1 Akademie

In-house training and development is a key element of the M1 Group's business model. That is why M1 operates the M1 Akademie. The main topics of the training courses provided are new treatment procedures, innovations and product presentations in the fields of aesthetic medicine as well as plastic and aesthetic surgery. Due to this uniform training and further education of all doctors and medical staff, M1 is able to offer customers the highest quality regardless of location.

M1 Akademie at a glance:

  • Worldwide private training centre for physicians, specialists and dentists
  • Neueste Behandlungsverfahren, Innovationen und
  • Latest treatment procedures, innovations and product presentations for the areas:
    • Aesthetic medicine
    • Plastic and aesthetic surgery
  • Providing practical experience, different techniques and detailed complication management
  • Brain pool with many years of know-how
  • Represented in Germany, Austria, Switzerland, the Netherlands, UK, Croatia, Hungary and Australia

We provide quality, techniques and expertise to doctors

More about M1 Akademie

Latest news

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

| Ad-hoc news

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.